Aspire Biopharma Holdings, Inc.(ASBPW)Earnings, Financials & Key Ratios
ASBPW•NASDAQ
$0.03
Price updated Jun 27, 2026
AboutAspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.Show more
- Revenue$6K
- EBITDA-$19M-66.2%
- Net Income-$24M-95.3%
- EPS (Diluted)-16.38+9.9%
- Gross Margin-1.87%
- EBITDA Margin-312016.95%
- Operating Margin-312016.95%
- Net Margin-394725.06%
ASBPW Price & Volume
Aspire Biopharma Holdings, Inc. (ASBPW) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Threaten Corporate Solvency
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent insolvency and dilution
Key Thesis Takeaways
- Aspire Biopharma Holdings faces a critical existential crisis characterized by negligible commercial revenue and a rapidly eroding capital base.
- The company's inability to scale diagnostic operations, evidenced by a 2026Q1 operating margin of -58.1%, suggests a fundamental failure to achieve a sustainable business model.
- Investors should exercise extreme caution as the firm's transition to negative equity and severe liquidity constraints indicate a high probability of further dilution or insolvency.
Verdict Logic
Negative: The company's current ratio of 0.17 and negative equity position of $6.4M as of 2025Q4 indicate that the firm lacks the necessary capital structure to support ongoing operations.
ASBPW Growth Metrics
Aspire Biopharma Holdings, Inc. (ASBPW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM73.23%
Return on Capital
10 Years-11.91%
5 Years-11.91%
3 Years-17.54%
Last Year-
Peers Comparison
Key metrics vs top competitors for Aspire Biopharma Holdings, Inc. (ASBPW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.03 | $45.6K | -0.00 | — | -394725.06% | — | — | |
| $1.39 | $360.29M | -32.86 | 2.82% | -1.17% | -1% | — | |
| $1.38 | $82.93M | -3.45 | -14.36% | -11.91% | -19.51% | — | |
| $62.93 | $1.8B | 16.01 | -13.8% | 45.58% | 6.41% | — | |
| $2.83 | $175.3M | -1.87 | -6.37% | -24.14% | -13.4% | — | |
| $0.79 | $3.77M | -0.01 | -29.45% | -237.25% | -500.33% | — |
Compare ASBPW vs Peers
Aspire Biopharma Holdings, Inc. (ASBPW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ASBPW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ASBPW Frequently Asked Questions
Aspire Biopharma Holdings, Inc. (ASBPW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Aspire Biopharma Holdings, Inc.'s revenue?
Aspire Biopharma Holdings, Inc. (ASBPW) reported $0.0M in revenue for fiscal year 2025.
Is ASBPW profitable?
Aspire Biopharma Holdings, Inc. (ASBPW) reported a net loss of $11.8M for fiscal year 2025.
Dividend & Returns
What is Aspire Biopharma Holdings, Inc.'s free cash flow?
Aspire Biopharma Holdings, Inc. (ASBPW) had negative free cash flow of $6.2M in fiscal year 2025, likely due to heavy capital investments.